UPDATE: Just got off the phone with CEO Thijs Spoor. Outstanding 22 minute conversation. Easily could have been 45 minutes, but he had more than answered all of the questions I had written down beforehand and the last thing I wanted to do was be rude, keep him on the line unnecessarily and do damage to this friendly informational relationship that we are developing here.
I am still digesting alot of the information and some of it I am going to research a bit more so that i have it 100% right and that I am diseminating it accurately and appropriately.
A couple personal thoughts for tonight:
1) That is one intelligent guy. He knows his numbers and has the company direction fully in focus!! Just listening to his theory and explanation of Risk Adjusted Valuations for Flouropharma is worth the price of admission!!! (My confidence is enthusiastically high)
2) Regardless of the potential for significant momentum moves, this is without a doubt a longer term investment! (I will be trimming on large spikes and adding on significant dips)
A couple clear points from our discussion:
1) After our recent financing via Private Placements we have enough capital through August '14. At that time, another round of financing will be necessary. As always, non-dilutive forms of financing that have beneficial terms for the company are being sought, (but as I have posted in the past I am not bothered by Private Placements to knowledgable investors and insiders (especially repeat investors) as a form of raising necessary capital to continue operations. Dilution Happens People!!
2) The Confidential Treatment Order (CTO) that was recently granted us by the SEC is a positive event for us. It is protecting the favorable licensing terms that we have with Massachusetts General Hospital. (Thats it plain and simple.)
3) Data results from our Phase II BFPET trial are on schedule to be released in the 1st Half of '14 as previously stated. The exact nature of the data to be released and the specific date of the release are confidential as of right now.
***** As you recall, the Positive Data release for our Phase II in CARDIOPET was also slated for 1st half of '14 and that came out on February 6th, 2014. That Data release came out in conjunction with a scheduled conference appearance. Mr. Spoor stated that he likes to release data in conjunction with conference appearances. That being said, we can assume that when there is a PR for an upcoming conference within the 1st half of '14, that the chances are above average that we will also be getting a catalyst of a data release for our Phase II in BFPET around the same time.
******* An interesting point to know, Thijs wasn't available this afternoon to chat on the phone because he was in meetings with his Investor Relations Department to discuss the topic of which upcoming Bio-Conferences to put on the schedule.
As I stated earlier, I have to digest a few other bits of information and do a little more homework on several items of information but will get those out to the board ASAP.
Hopefully, this very quick disemination of cursory information will be useful to many of you in making your investing decisions regarding FPMI.
Have A great evening everyone!!!
RR
